pressofAtlanticCity.com: Your source for the latest Breaking News plus Local, Business, Sports, Entertainment & Video News for Southern New Jersey

default avatar
Welcome to the site! Login or Signup below.
|
Not you?||
Logout|My Dashboard
AAA  Jun. 7, 2013
Dow spotlight: Merck
By TREVOR DELANEY
  •       Text Size    
  •       AIM Article
  •       Share Article

Buy AP Photo Reprints

Merck is the top performer in the Dow Jones industrial average this week. It has climbed 4 percent, compared with a drop of slightly more than 1 percent for the overall average.

A big driver has been promising results from a preliminary study on the effectiveness of lambroliz-umab, an experimental drug for advanced melanoma – skin cancer that has spread or is inoperable. It’s part of a new cancer research area called immune-oncology that within several years could bring safer treatments and mean billions in revenue for drugmakers.

Such a payoff would be welcome news for Merck investors. The company must replace several billion dollars in revenue lost to recent generic competition for several drugs, including Singulair, an asthma and allergy pill.

Associated Press
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.